A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013

Trial Profile

A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs ADC 1013 (Primary) ; ADC 1013 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Alligator Bioscience
  • Most Recent Events

    • 21 Sep 2017 According to an Alligator Bioscience media release, data will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017.
    • 23 Mar 2017 Status changed from recruiting to completed.
    • 28 Sep 2016 Planned number of patients changed from 50 to 40.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top